← brief for 2026-11-02 · Slowing decline

Effect of combined sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonist therapy in patients with chronic kidney disease: a real-world analysis.

Article C Peer reviewed Observational

Key takeaways

This study looked at real-world data for people with kidney disease. It compared using two types of diabetes drugs together versus using one alone. It tracked kidney and heart outcomes over two years. This is an observational study, so it shows a link, not proof of cause.

Who did this work

Ho CW · Chuang MH · Wu VC · Tu YK · Wu YC · Chen JY

Source

Article · PubMed, the drug frontier · 2026 Nov 2
https://pubmed.ncbi.nlm.nih.gov/42968232/